Skip to main content

Table 2 Implant characteristics, patient distribution, and ambulatory follow-up care

From: Detection of arrhythmia using an implantable cardiac monitor following a cryptogenic stroke: a single-center observational study

Parameter Overall population (n = 88)
Implant manufacturer, n (%)
 Biotronik 58 (65.9)
 Medtronic 17 (19.3)
 St. Jude 13 (14.8)
Implant designation, n (%)
 Biomonitor2-AF 58 (65.9)
 Reveal LINQ 2 (2.3)
 Reveal XT 15 (17.0)
 SJM confirm 13 (14.8)
Tele-monitoring, n (%)
 On 58 (65.9)
 Off 30 (34.1)
Ambulatory follow-up care, n (%)
 Rostock University Medical Center 58 (65.9)
 Doctor’s office 30 (34.1)
 Observation period (months), median (range) 21.5 (1–33)